The primary aim was to determine the effectiveness of a single high-dose of oral vitamin D3 (stoss therapy
) in children with inflammatory bowel disease (IBD) and hypovitaminosis D. Our secondary aim was to examine the safety of stoss therapy
We conducted a randomized, prospective study of 44 patients, ages 6 to 21 years, with IBD and 25-hydroxyvitamin D (25-OHD) concentrations <30 ng/mL. Patients were randomized to receive 50,000 IU of vitamin D3 once weekly for 6 weeks (standard of care, SOC group) or 300,000 IU once (stoss group). Serum 25-OHD levels were obtained at baseline, 4 and 12 weeks. Safety monitoring labs were performed at week 4.
Thirty-nine of 44 enrolled patients (19 stoss, 20 SOC) completed the study. Baseline vitamin D levels were not significantly different between the groups. Stoss therapy
resulted in a substantial rise in 25-OHD levels at week 4, equivalent to the weekly regimen (53.6 ± 17.3 vs 54.6 ± 17.5 ng/mL). At week 12, serum 25-OHD levels decreased in both groups, significantly lower in the stoss group, but remained close to 30 ng/mL (29.8 ± 7.1 vs 40.4 ± 11.9 ng/mL, P
= 0.04). A significant interaction with treatment group over time was observed (P
= 0.0003). At the week-4 time point, all patients who received stoss therapy
had normal serum calcium and PTH levels. Eighty percentage of patients preferred stoss therapy
to the weekly regimen.
Conclusions: Stoss therapy
was safe and effective in raising 25-OHD in children with IBD commensurate to that of the weekly regimen.